President Barack Obama plans to meet with Democratic lawmakers in Congress to discuss how to protect his signature healthcare law from Republican efforts to dismantle it, Politico reported.
A year ago, the mosquito-borne Zika virus was only beginning to reveal itself as a threat to pregnant women and their unborn babies. Since then, U.S. officials have issued 60 travel alerts along with guidance for athletes and tourists traveling to the Olympics in Rio. They have also deployed more than 1,000 experts to Puerto Rico and elsewhere, tested more than 147,000 lab specimens, initiated 25 major studies and issued more than 230 scientific publications. And the work is not done, said Dr. Thomas Frieden, director of the U.S. Centers for Disease Control and Prevention.
OPKO Health Inc. said its experimental drug for GHD in adults failed to provide a statistically significant benefit over a placebo in a late-stage study.
A diet rich in magnesium – found in foods like leafy greens, fish, nuts and whole grains – may help lower the risk of chronic health problems like heart disease and diabetes, a research review suggests.
2016 was not a banner year for M&A in the biopharma industry compared to 2014 and 2015. BioPharmaDIVE looks at seven potential acquisition targets for 2017.
Innocoll received a Refusal to File letter from the United States Food and Drug Administration (FDA) for XARACOLL, the company’s product candidate for the treatment of postsurgical pain.
Fewer people in the U.S. have celiac disease without realizing it, a new study finds.
Web-based therapy for insomnia is an effective option that could reach “previously unimaginable numbers of people,” researchers suggest.
The FDA rejected Cempra Inc.’s antibiotic for community-acquired bacterial pneumonia, citing inadequate data on the drug’s impact on liver and manufacturing issues.
Biogen finally set a price tag for its newly approved spinal atrophy drug Spinraza – the first drug ever approved for the disease – and as expected, it’s in the high six figures.
Shares of Fortress Biotech (formerly known as Coronado Biosciences) surged after the company announced that a glioblastoma patient who showed no response to standard of care treatments had a remarkable turnaround after being treated with the company’s Phase I drug candidate, MB-101.
For the second time in less than a year, Provectus Biopharmaceuticals Inc. is down a chief executive officer.
Boehringer Ingelheim agreed to divest five types of animal health products to settle charges that a proposed asset swap with Sanofi would harm competition.
A federal appeals court revived a lawsuit accusing Medtronic Plc of defrauding shareholders by covering up negative side effects from its Infuse bone growth product for nearly a decade.
Tedor Pharmaceuticals is expanding its Rhode Island manufacturing facility and expanding its employment with more than 20 new positions, the company announced.
After suffering a setback in 2016, Regeneron could be poised for a turnaround in 2017 and it hinges on correcting manufacturing problems that caused regulators to block approval of a new drug to treat rheumatoid arthritis.
A Harvard professor has retracted research that was once considered a breakthrough in diabetes research.
The serial testing of some volunteers is raising new questions about the level of oversight of India’s generic drug trials industry, after some CROs came under recent international regulatory scrutiny.
Anthera Pharmaceuticals Inc. said its drug to treat certain cystic fibrosis patients failed a late-stage study, sending the company’s shares tumbling nearly 70 percent in after-hours trading.
The U.S. government issued rules for addressing cyber vulnerabilities in medical devices, providing manufacturers with guidelines for fixing security bugs in equipment, including pacemakers, insulin pumps and imaging systems.